Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.48 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | REN | P00797 | 1/20 | 0.30 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3819939 | 0.91 | ADORA3 (0.40) | TLR8TLR7ADORA3CYP3A4 | |
| SCHEMBL3485208 | 0.87 | TLR8 (0.34) | TLR8 | |
| SCHEMBL2906856 | 0.84 | TLR7 (0.34) | TLR8TLR7CYP3A4 | |
| SCHEMBL21295321 | 0.81 | KDM4E (0.31) | TLR8CYP3A4 | |
| SCHEMBL31045510 | 0.81 | TLR8 (0.31) | TLR8 | |
| SCHEMBL8676844 | 0.74 | PTPN11 (0.37) | BACE1 | |
| SCHEMBL28928674 | 0.72 | CHUK (0.32) | — | |
| SCHEMBL4606082 | 0.72 | — | — | |
| SCHEMBL6512730 | 0.71 | — | — | |
| SCHEMBL2931429 | 0.71 | DPYD (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7229974-B2 | G cap-stabilized oligonucleotides | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-12 | — | — | US | claimed |
| US-20020151512-A1 | G cap-stabilized oligonucleotides | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-10-17 | — | — | US | claimed |
| EP-0726274-B1 | G-cap stabilized oligonucleotides | AVENTIS PHARMA GMBH (DE) | 2001-10-10 | — | — | EP | claimed |
| US-6013639-A | MODIFYING END GROUPS; DIAGNOSIS, THERAPY CANCER, RESTENOSIS | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-01-11 | — | — | US | claimed |
| EP-0882734-B1 | 5'-Deoxy-cytidine derivatives | HOFFMANN LA ROCHE (CH) | 2009-08-26 | — | — | EP | disclosed |
| US-6348312-B1 | OLIGONUCLEOTIDE HAVING LENGTH OF 6-100 NUCLEOTIDES, WHEREIN AT LEAST ONE NON-TERMINAL PYRIMIDINE NUCLEOSIDE IS MODIFIED, AND ALSO 5' AND/OR 3' ENDS ARE MODIFIED, BY REPLACEMENT OF 3' AND/OR 5' PHOSPHODIESTER BRIDGE BY PHOSPHOROTHIOATE BRIDGE | HOESCHT AKTIENGESELLSCHAFT (DE) | 2002-02-19 | — | — | US | disclosed |
| US-6211166-B1 | COADMINISTERED WITH A 5-FLUOROURACIL DERIVATIVE; ANTICARCINOGENIC AGENTS | HOFFMAN-LA ROCHE INC. | 2001-04-03 | — | — | US | disclosed |
| US-6127346-A | FOR THE TREATMENT OF VIRUSES | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-10-03 | — | — | US | disclosed |
| US-6114520-A | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 2000-09-05 | — | — | US | disclosed |
| US-5874553-A | ANTIBODIES; INHIBITOR OF GENE EXPRESSION | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-02-23 | — | — | US | disclosed |
| EP-0882734-A2 | 5'-Deoxy-cytidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-12-09 | — | — | EP | disclosed |